Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose AS's Novel Drug Delivery Technology
10/28/2010 12:10:09 PM
YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose Inc. announced the results from an analysis comparing the Phase II clinical trial obtained with its novel delivery technology to that of other formulations. The analysis suggests rapid absorption rate alone may not explain the efficacy in migraines treated with sumatriptan delivered with the Company’s novel bi-directional technology. The results will be presented at the 2nd European Headache and Migraine Trust International on 28th of October 2010.